2/26/2010

Bristol-Myers Squibb's kidney transplant drug belatacept extended survival better than older treatments, FDA reviewers said, but it also appeared to cause a higher rate of severe kidney rejection and neurological disease. A panel of experts is scheduled to evaluate the drug's safety and efficacy next week.

Related Summaries